Zomedica Stock Price

0.0044 (2.2%)
Volume 120,450
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Zomedica Corp ZOM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0044 2.2% 0.2044 09:10:15
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
203 120,450 - 0.175 - 0.50
Last Trade Time Type Quantity Stock Price Currency
09:12:50 formt 100 $ 0.2044 USD


Draw Mode:

Zomedica Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 200.30M 979.95M 966.88M $ 4.13M $ - -0.05 -14.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.80M 4.30%

more financials information »

Zomedica News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZOM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.20170.20880.200.2018883,863,9190.00271.34%
1 Month0.2310.24990.1990.22224565,877,986-0.0266-11.52%
3 Months0.210.2610.1990.22286946,791,384-0.0056-2.67%
6 Months0.24570.410.1990.259505913,126,317-0.0413-16.81%
1 Year0.400.500.1750.286046515,389,281-0.1956-48.9%
3 Years0.342.910.06280.747805839,152,184-0.1356-39.88%
5 Years2.402.980.06280.747805123,661,502-2.20-91.48%

Zomedica Description

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.